Psychedelic Therapies and Research

Psychedelic Assisted Therapies and Research

UNM Academic Interest Group

Psychedelic Assisted Therapies and Research

About

The UNM Academic Interest Group (AIG) on Psychedelic Assisted Therapies and Research was formed in 2023. As potential clinical applications and research for psychedelic therapies extend across a wide variety of disciplines on the health sciences campus as well as social sciences areas on the main campus, we welcome members from all of these disciplines. We believe that there is a great opportunity for collaboration, co-education, and generation of new ideas and projects.

Therapists work with a patient during a trial to determine if MDMA could ease symptoms of PTSD. A majority of patients who received the drug were no longer diagnosed with the disorder after the trial ended. MULTIDISCIPLINARY ASSOCIATION FOR PSYCHEDELIC STUDIES

Background

UNM HSC’s involvement in psychedelic research began with Rick Strassman’s studies of N,N-dimethyltryptamine-(DMT) and Psilocybin from 1990 to 1995. These studies were the first human research of psychedelic compounds since psychedelic research was halted in the early 1970s. Currently, there are active research plans and proposals at UNM for the study of MDMA assisted therapy for co-occurring post-traumatic stress disorder and opioid use disorder, neuroimaging to assess the effects of ketamine on neural pathways in individuals with PTSD, ketamine assisted therapy for polysubstance use involving opioids, and psilocybin for methamphetamine. Other identified research interests at UNM have included end of life anxiety, neurochemical and psychological mechanisms of change, and chronic pain.

Group Goals

Support education and research in psychedelic assisted therapies
Support basic and preclinical science research
Sponsoring quarterly presentations and journal clubs
Development of a website to share information regarding psychedelic research at UNM HSC
Develop guidelines for faculty regarding in developing and funding psychedelic research proposals
Develop guidelines to obtain FDA, HRPO, and DEA approval
Facilitate discussions at UNM HSC regarding incorporation into clinical practice as psychedelic therapies become FDA approved

Upcoming Psychedelic Therapies and Research Talks

October 26, 2023 | 12:00pm | Rick Strassman, MD - (More information to follow)
January 9th, 2024 | 12:00 pm| Scott Shannon, MD - (More information to follow)

A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience. Gallimore AR, Strassman RJ. 2016

A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010. Barker SA, McIlhenny EH, Strassman R. 2012

Psychedelic Therapies at the Crossroads of Trauma and Substance Use: Historical Perspectives and Future Directions, Taking a Lead From New Mexico. Bhatt SR, Armstrong M, Parker T, Maviglia M, Kass R, Leeman L, Romo P, Ziedonis D. 2022

Human psychopharmacology of N,N-dimethyltryptamine. Strassman RJ. 1996

Human hallucinogenic drug research in the United States: a present-day case history and review of the process. Strassman RJ. 1991

Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Strassman RJ, Qualls CR. 1994

Therapeutic Mechanisms of Classic Hallucinogens in the Treatment of Addictions: From Indirect Evidence to Testable Hypotheses. Bogenschutz MP, Pommy JM. 2012

Psychometric assessment of the Hallucinogen Rating Scale. Riba J, Rodríguez-Fornells A, Strassman RJ, Barbanoj MJ. 2001

Psilocybin-Assisted Treatment for Alcohol Dependence: A Proof-of-Concept Study. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. 2015

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O'Donnell K, Owens LT, Podrebarac S, Rotrosen J, Tonigan JS, Worth L. 2022

Psilocybin Assisted Psychotherapy for Alcohol Use Disorder
- Snehal Bhatt, MD

Break the Cycle of Dependency Using MDMA-Assisted Therapy
- Larry Leeman, MD

The Use of MDMA Assisted Psychotherapy for PTSD and Addiction - Grand Rounds
- Larry Leeman, MD

Psychedelic Assisted Therapy for Dying: Early History and Future Potential
- Roshi Joan Halifax, Ph.D.

MDMA-Assisted Therapy 6 to 12 months After Childbirth for People with Co-occurring Opioid Use and Post Traumatic Stress Disorders (MAT-POD). Click here for active studies

Publications

A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience. Gallimore AR, Strassman RJ. 2016

A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010. Barker SA, McIlhenny EH, Strassman R. 2012

Psychedelic Therapies at the Crossroads of Trauma and Substance Use: Historical Perspectives and Future Directions, Taking a Lead From New Mexico. Bhatt SR, Armstrong M, Parker T, Maviglia M, Kass R, Leeman L, Romo P, Ziedonis D. 2022

Human psychopharmacology of N,N-dimethyltryptamine. Strassman RJ. 1996

Human hallucinogenic drug research in the United States: a present-day case history and review of the process. Strassman RJ. 1991

Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Strassman RJ, Qualls CR. 1994

Therapeutic Mechanisms of Classic Hallucinogens in the Treatment of Addictions: From Indirect Evidence to Testable Hypotheses. Bogenschutz MP, Pommy JM. 2012

Psychometric assessment of the Hallucinogen Rating Scale. Riba J, Rodríguez-Fornells A, Strassman RJ, Barbanoj MJ. 2001

Psilocybin-Assisted Treatment for Alcohol Dependence: A Proof-of-Concept Study. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. 2015

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O'Donnell K, Owens LT, Podrebarac S, Rotrosen J, Tonigan JS, Worth L. 2022

Videos

Psilocybin Assisted Psychotherapy for Alcohol Use Disorder
- Snehal Bhatt, MD

Break the Cycle of Dependency Using MDMA-Assisted Therapy
- Larry Leeman, MD

The Use of MDMA Assisted Psychotherapy for PTSD and Addiction - Grand Rounds
- Larry Leeman, MD

Psychedelic Assisted Therapy for Dying: Early History and Future Potential
- Roshi Joan Halifax, Ph.D.

Active Studies

MDMA-Assisted Therapy 6 to 12 months After Childbirth for People with Co-occurring Opioid Use and Post Traumatic Stress Disorders (MAT-POD). Click here for active studies

Media

Podcasts

Psychedelic Assisted Therapies and Research

Larry Leeman, MD, MPH
UNM Family & Community
1 University of New Mexico
MSC09 5040
Albuquerque, NM 87131
LLeeman@salud.unm.edu

Snehal Bhatt, MD
Division Chief
Addictions Psychiatry
1 University of New Mexico
MSC09 5030
Albuquerque, NM 87131
SBhatt@salud.unm.edu

Are you a patient looking for care?

Visit UNM

Psychedelic Assisted Therapies and Research

About

Background

Group Goals

Upcoming Psychedelic Therapies and Research Talks

Psilocybin Assisted Psychotherapy for Alcohol Use Disorder - Snehal Bhatt, MD

Break the Cycle of Dependency Using MDMA-Assisted Therapy - Larry Leeman, MD

The Use of MDMA Assisted Psychotherapy for PTSD and Addiction - Grand Rounds - Larry Leeman, MD

Psychedelic Assisted Therapy for Dying: Early History and Future Potential - Roshi Joan Halifax, Ph.D.

Psilocybin Assisted Psychotherapy for Alcohol Use Disorder - Snehal Bhatt, MD

Break the Cycle of Dependency Using MDMA-Assisted Therapy - Larry Leeman, MD

The Use of MDMA Assisted Psychotherapy for PTSD and Addiction - Grand Rounds - Larry Leeman, MD

Psychedelic Assisted Therapy for Dying: Early History and Future Potential - Roshi Joan Halifax, Ph.D.

Psychedelic Assisted Therapies and Research

Are you a patient looking for care?

Psilocybin Assisted Psychotherapy for Alcohol Use Disorder
- Snehal Bhatt, MD

Break the Cycle of Dependency Using MDMA-Assisted Therapy
- Larry Leeman, MD

The Use of MDMA Assisted Psychotherapy for PTSD and Addiction - Grand Rounds
- Larry Leeman, MD

Psychedelic Assisted Therapy for Dying: Early History and Future Potential
- Roshi Joan Halifax, Ph.D.

Psilocybin Assisted Psychotherapy for Alcohol Use Disorder
- Snehal Bhatt, MD

Break the Cycle of Dependency Using MDMA-Assisted Therapy
- Larry Leeman, MD

The Use of MDMA Assisted Psychotherapy for PTSD and Addiction - Grand Rounds
- Larry Leeman, MD

Psychedelic Assisted Therapy for Dying: Early History and Future Potential
- Roshi Joan Halifax, Ph.D.